Portfolio Manager Factsheet

December 2018

The broader market continued its correction in December, with sustained volatility in higher risk sectors including biotech. DBV shares underperformed in December following the surprise withdrawal of the company’s regulatory filing of their Viaskin Peanut patch for the treatment of peanut allergy due to manufacturing issues.

Read more »

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.